

(51) International Patent Classification:
A61P 35/00 (2006.01) *C07K 16/28* (2006.01)(21) International Application Number:
PCT/US2021/034852(22) International Filing Date:
28 May 2021 (28.05.2021)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
63/032,508 29 May 2020 (29.05.2020) US(71) Applicant: **23ANDME, INC.** [US/US]; 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US).(72) Inventors: **CHEN, Yu**; c/o 23andMe, Inc., 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US). **FENAUX, Jilean, Beth**; c/o 23andMe, Inc., 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US). **FUH-KELLY, Germaine**; c/o 23andMe, Inc., 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US). **HUANG, Yao-Ming**; c/o 23andMe, Inc., 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US).da Ave., Sunnyvale, CA 94086 (US). **CHUNG, Wei-Jen**; c/o 23andMe, Inc., 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US). **KARRER, Erik, Edward**; c/o 23andMe, Inc., 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US). **LAY, Cecilia**; c/o 23andMe, Inc., 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US). **PITTS, Steven, J.**; c/o 23andMe, Inc., 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US). **SCHARF, Louise**; c/o 23andMe, Inc., 223 N. Mathilda Ave., Sunnyvale, CA 94086 (US).(74) Agent: **WHITING, Adam**; FisherBroyles, LLP, 4100 Redwood Rd. 20A-203, Oakland, CA 94619 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: ANTI-CD200R1 ANTIBODIES AND METHODS OF USE THEREOF

FIG. 8C



(57) Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*